Do you offer local consolidative therapy for patients with polymetastatic driver mutation-positive NSCLC who respond well to targeted therapy?  

If so, when and to what extent? 

Answer from: Medical Oncologist at Academic Institution
Radiation Oncologist at National Cancer Institute
The question was about polymetastatic, driver-muta...
Sign in or Register to read more